Literature DB >> 9620097

The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.

L D Dresser1, M J Rybak.   

Abstract

The oxazolidinones are a new synthetic class of antimicrobials structurally unrelated to any agent presently marketed. Data pertaining to these compounds, with respect to their pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, and bacteriologic activity, focusing on the analogs linezolid (PNU 100766) and eperezolid (PNU 100592), were retrieved by MEDLINE search and review of relevant abstracts presented at recent clinical conferences. Since the drugs are still investigational, we obtained in vitro and animal data as well as available human studies. The oxazolidinones have bacteriostatic activity against a number of important pathogens including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and vancomycin-resistant enterococci. They appear to be efficacious and well tolerated both orally and parenterally. Their role remains to be elucidated by clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620097

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  31 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.

Authors:  Ronny Beer; Klaus W Engelhardt; Bettina Pfausler; Gregor Broessner; Raimund Helbok; Peter Lackner; Christian Brenneis; Stefan T Kaehler; Apostolos Georgopoulos; Erich Schmutzhard
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

3.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

4.  Predicting oral absorption of drugs: a case study with a novel class of antimicrobial agents.

Authors:  Allen R Hilgers; Donald P Smith; John J Biermacher; Jeffrey S Day; Jana L Jensen; Sandra M Sims; Wade J Adams; Janice M Friis; Joe Palandra; John D Hosley; Eric M Shobe; Philip S Burton
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

5.  An uncommon side-effect of linezolid.

Authors:  Vamsee Priya Marina; Rahil Kasmani
Journal:  Int Urol Nephrol       Date:  2011-06-05       Impact factor: 2.370

6.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.

Authors:  Stephan Schmidt; Sreedharan Nair Sabarinath; April Barbour; Darren Abbanat; Prasarn Manitpisitkul; Sue Sha; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 8.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.

Authors:  Jamese J Hilliard; Jeffrey Fernandez; John Melton; Mark J Macielag; Raul Goldschmidt; Karen Bush; Darren Abbanat
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

10.  Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme.

Authors:  Craig R Rayner; Alan Forrest; Alison K Meagher; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.